查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951261

即時分子診斷市場－全球產業規模、佔有率、趨勢、機會及預測（依技術、應用、檢測地點、最終用戶、地區及競爭格局分類，2021-2031年）

Point-Of-Care Molecular Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By Test Location, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球即時分子診斷市場預計將從 2025 年的 28.8 億美元成長到 2031 年的 54.5 億美元，複合年成長率為 11.21%。

即時分子診斷利用自動化檢測平台，在患者照護現場即可即時辨識致病遺傳物質和突變。這些可攜式系統無需中央檢查室處理即可提供快速且準確的結果，從而加快臨床決策。推動市場發展的關鍵因素是全球感染疾病率的上升以及醫療服務分散化的趨勢，這需要便捷的檢測解決方案。此外，微流體技術的不斷進步提高了這些設備的運作速度和易用性，促進了它們在各種醫療機構中的應用。

市場概覽
預測期 2027-2031
市場規模：2025年 28.8億美元
市場規模：2031年 54.5億美元
複合年成長率：2026-2031年 11.21%
成長最快的細分市場 混合技術
最大的市場 北美洲

然而，由於法規環境嚴格和合規成本高昂，該行業面臨嚴峻挑戰。向更嚴格的監管框架過渡給製造商帶來了沉重的財務負擔，抑制了創新並延緩了產品上市。例如，根據歐洲醫療技術協會（MedTech Europe）報告，到2024年，根據新的體外診斷醫療設備法規（IVDR），製造商的認證成本可能比先前的指令增加高達100%。成本的增加提高了准入門檻，並可能阻礙經濟高效的診斷解決方案的廣泛應用。

市場促進因素

全球感染疾病和流行病負擔日益加重，成為推動市場發展的主要因素，也因此迫切需要能夠快速識別流感、呼吸道合胞病毒（RSV）和新冠病毒（COVID-19）等病原體的可靠診斷工具。隨著呼吸道病毒的持續流行，醫療系統正優先考慮能夠區分重疊症狀並改善患者管理的多重分子檢測。這項強勁需求體現在提供全面呼吸道檢測組合的主要產業參與者的商業性成功。根據丹納赫公司於2025年1月發布的2024年第四季財務報告，Cepheid公司僅在第四季呼吸道檢測收入就達到了約5.5億美元。這主要得益於市場對其四聯檢測套組的強勁需求，凸顯了市場對分子照護現場解決方案在季節性疫情管理中的依賴。

同時，隨著醫療分散化和床邊檢測的興起，先進的診斷技術正從中心檢查室轉移到診所和急診中心，整個產業也因此經歷變革。緊湊型平台能夠在非傳統環境下提供檢查室級的檢測結果，顯著縮短治療時間，從而推動了這一轉變。製造商正積極擴大裝機量，以滿足這種更貼近患者的檢測需求。根據生物梅里埃公司於2025年3月發布的2024年財務報告，SPOTFIRE照護現場系統的年銷售額預計將達到約9,500萬歐元，裝置量將達到3,000台。儘管取得了這些進展，但全球範圍內的醫療服務可近性仍有顯著差異。 2024年10月，世界衛生組織（世衛組織）指出，僅48%的新確診結核病病例使用世衛組織推薦的快速分子診斷作為初始檢測方法，這凸顯了巨大的未滿足需求，並將推動未來的市場擴張。

市場挑戰

嚴格的法規環境和相關的合規成本是該領域發展的一大障礙，嚴重限制了市場成長勢頭。隨著監管機構為確保設備安全性和性能而實施更嚴格的標準，製造商被迫將大量資源從研發轉移到應對複雜的核准流程。這種資金和技術專長的轉移減緩了創新步伐，阻礙了突破性診斷平台有效率地進入商業化階段。所需的大量文件和臨床證據延長了研發週期，延緩了關鍵即時檢測解決方案的普及應用。

這些監管壓力正在積極重塑全球市場策略，導致製造商對認證時間難以預測的市場猶豫不決或選擇退出。過度關注合規性使得曾經的醫療科技創新中心地區吸引力下降。根據歐洲醫療技術協會（MedTech Europe）預測，到2024年，與新法規結構相關的挑戰將導致選擇歐盟作為首發產品優先市場的領先診斷製造商數量下降40%。這一趨勢表明，監管負擔正在直接阻礙分子診斷技術的廣泛應用和普及。

市場趨勢

基於 CRISPR 的診斷技術的出現正在革新市場，它無需複雜的熱感熱處理，即可實現與傳統 PCR 相當的高靈敏度無儀器分子檢測。該技術利用 Cas 酶直接從樣本中識別特定基因標靶，顯著降低了照護現場)的設備複雜性和製造成本。這項創新技術的商業性擴充性正在推動關鍵的策略性收購，旨在部署用於分散式篩檢的下一代檢測方法。根據 OraSure Technologies 公司關於其於 2024 年 12 月收購 Sherlock Biosciences 的新聞稿，該公司估計僅 Sherlock 基於 CRISPR 的披衣菌感染和淋病自檢檢測套組的潛在市場規模就超過 15 億美元，凸顯了這些先進的基因編輯診斷技術蘊藏的巨大經濟機遇。

同時，消費級和家用分子檢測套組的普及正在徹底改變患者的就醫方式，使個人能夠在家中進行檢查室層級的檢測。製造商正迅速獲得監管部門核准，推出用於診斷性行為感染傳染病和呼吸道疾病的商業平台，從而繞過傳統的臨床瓶頸和醫生轉診。這一趨勢吸引了大量投資，用於擴大主導消費者的診斷產品的生產和分銷網路，以滿足不斷成長的需求。根據Ctech 2025年6月的一篇報導，Visby Medical籌集了約5500萬美元，以加速其獲得FDA批准的家用性健康檢測產品的商業推廣，這凸顯了該行業正迅速向以用戶為中心的診斷模式轉變。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球即時分子診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術分類（基於PCR、基於基因定序、基於雜合反應、基於微陣列）
    • 依應用領域（感染疾病、腫瘤學、血液學、產前檢測、內分泌學等）
    • 按測試地點（OTC、POC）
    • 按最終使用者（分散式檢查實驗室、醫院、居家醫療、輔助生活設施、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美即時分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲即時分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區即時分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲即時分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲即時分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球即時分子診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Siemens Healthineers AG
  • Quidel Corporation
  • F. Hoffman-La Roche Ltd.
  • Danaher Corporation
  • Beckton & Dickinson Company
  • Trinity Biotech plc
  • Thermo Fisher Scientific Inc
  • bioMerieux SA
  • DiaSorin SpA
  • AccuBioTech Co., Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23762

The Global Point-Of-Care Molecular Diagnostics Market is projected to experience significant growth, rising from a valuation of USD 2.88 Billion in 2025 to USD 5.45 Billion by 2031, reflecting a CAGR of 11.21%. Point-of-care molecular diagnostics utilize automated testing platforms to identify pathogenic genetic material or mutations immediately at the site of patient care. These portable systems provide rapid and accurate results without the need for centralized laboratory processing, facilitating prompt clinical decision-making. The market is largely driven by the rising global prevalence of infectious diseases and a shift toward decentralized healthcare that demands accessible testing solutions. Additionally, ongoing advancements in microfluidics have improved the speed and usability of these devices, supporting their adoption across various medical settings.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.88 Billion
Market Size 2031USD 5.45 Billion
CAGR 2026-203111.21%
Fastest Growing SegmentHybridization-Based Technology
Largest MarketNorth America

However, the industry faces substantial challenges due to strict regulatory environments and high compliance costs. The move toward more rigorous frameworks has placed significant financial burdens on manufacturers, which threatens to stifle innovation and delay product launches. For example, MedTech Europe reported that in 2024, certification costs for manufacturers under the new In Vitro Diagnostic Regulation rose by up to 100 percent compared to previous directives. This increase in expenses establishes a high barrier to entry and may hinder the widespread expansion of cost-effective diagnostic solutions.

Market Driver

The escalating global burden of infectious diseases and pandemics serves as a primary catalyst for the market, creating a critical need for robust diagnostic tools capable of rapidly identifying pathogens such as influenza, RSV, and COVID-19. As respiratory viruses continue to co-circulate, healthcare systems are prioritizing multiplex molecular assays that can differentiate between overlapping symptoms to improve patient management. This strong demand is reflected in the commercial success of major industry players offering comprehensive respiratory panels. According to Danaher Corporation's Q4 2024 earnings results released in January 2025, Cepheid's respiratory testing revenue hit approximately $550 million in the fourth quarter alone, driven by high volumes of their four-in-one test, underscoring the market's reliance on molecular point-of-care solutions for managing seasonal outbreaks.

Simultaneously, the growing shift toward decentralized healthcare and near-patient testing is transforming the industry by relocating advanced diagnostics from central labs to clinics and urgent care centers. This transition is supported by compact platforms that deliver lab-quality results in non-traditional settings, significantly accelerating time-to-treatment. Manufacturers are aggressively expanding their installed bases to meet this demand for accessible testing closer to the patient. According to bioMerieux's 2024 financial results from March 2025, sales of the SPOTFIRE point-of-care system reached nearly €95 million for the year, with an installed base of 3,000 units. despite this progress, significant gaps remain in global access; the World Health Organization noted in October 2024 that only 48 percent of newly diagnosed tuberculosis cases were tested using a WHO-recommended rapid molecular diagnostic as the initial test, highlighting the immense unmet need driving future market expansion.

Market Challenge

The sector encounters major obstacles regarding stringent regulatory environments and associated compliance costs, which act as a significant brake on market momentum. As regulatory bodies enforce more rigorous standards to ensure device safety and performance, manufacturers are forced to reallocate critical resources from research and development toward navigating complex approval processes. This diversion of capital and technical expertise slows the pace of innovation, preventing potentially breakthrough diagnostic platforms from reaching the commercial stage efficiently. The sheer volume of documentation and clinical evidence required creates prolonged development cycles, delaying the availability of essential point-of-care solutions.

These regulatory pressures are actively reshaping global market strategies, causing manufacturers to hesitate or withdraw from markets with unpredictable certification timelines. The intense focus on compliance reduces the attractiveness of regions that were once hubs for medical technology innovation. According to MedTech Europe, in 2024, the percentage of large diagnostic manufacturers selecting the European Union as their priority region for first product launches declined by 40% due to the challenges associated with the new regulatory framework. This trend demonstrates how regulatory burdens are directly impeding the widespread expansion and accessibility of molecular diagnostic technologies.

Market Trends

The emergence of CRISPR-based diagnostic technologies is revolutionizing the market by enabling highly sensitive, instrument-free molecular detection that rivals traditional PCR without requiring complex thermal cycling. This technology utilizes Cas enzymes to identify specific genetic targets directly from samples, significantly reducing device complexity and manufacturing costs for point-of-care settings. The commercial scalability of this innovation is driving major strategic acquisitions aimed at deploying next-generation assays for decentralized screening. According to OraSure Technologies in a December 2024 press release regarding the acquisition of Sherlock Biosciences, the company estimates that the total addressable market for Sherlock's CRISPR-based Chlamydia and Gonorrhea self-test alone represents more than $1.5 billion, underscoring the immense financial opportunity in these advanced gene-editing diagnostics.

Simultaneously, the expansion of direct-to-consumer and home-use molecular testing kits is fundamentally altering patient access by allowing individuals to perform lab-quality assays in their own homes. Manufacturers are increasingly securing regulatory authorizations for over-the-counter platforms that diagnose sexual health and respiratory conditions, thereby bypassing traditional clinical bottlenecks and physician referrals. This trend is attracting substantial investment capital aimed at scaling manufacturing and distribution networks for consumer-initiated diagnostics to meet rising public demand. According to a Ctech article from June 2025, Visby Medical raised approximately $55 million specifically to accelerate the commercial reach of its FDA-cleared at-home sexual health test, highlighting the sector's rapid pivot toward user-centric diagnostic models.

Key Market Players

  • Siemens Healthineers AG
  • Quidel Corporation
  • F. Hoffman-La Roche Ltd.
  • Danaher Corporation
  • Beckton & Dickinson Company
  • Trinity Biotech plc
  • Thermo Fisher Scientific Inc
  • bioMerieux S.A.
  • DiaSorin S.p.A
  • AccuBioTech Co., Ltd.

Report Scope

In this report, the Global Point-Of-Care Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-Of-Care Molecular Diagnostics Market, By Technology

  • PCR-based
  • Genetic Sequencing-based
  • Hybridization-based
  • Microarray-based

Point-Of-Care Molecular Diagnostics Market, By Application

  • Infectious Diseases
  • Oncology
  • Hematology
  • Prenatal Testing
  • Endocrinology
  • Other

Point-Of-Care Molecular Diagnostics Market, By Test Location

  • OTC
  • POC

Point-Of-Care Molecular Diagnostics Market, By End User

  • Decentralized Labs
  • Hospitals
  • Home-care
  • Assisted Living Healthcare Facilities
  • Others

Point-Of-Care Molecular Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-Of-Care Molecular Diagnostics Market.

Available Customizations:

Global Point-Of-Care Molecular Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Point-Of-Care Molecular Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based)
    • 5.2.2. By Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, Other)
    • 5.2.3. By Test Location (OTC, POC)
    • 5.2.4. By End User (Decentralized Labs, Hospitals, Home-care, Assisted Living Healthcare Facilities, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Point-Of-Care Molecular Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By Test Location
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Point-Of-Care Molecular Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Test Location
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Point-Of-Care Molecular Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Test Location
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Point-Of-Care Molecular Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Test Location
        • 6.3.3.2.4. By End User

7. Europe Point-Of-Care Molecular Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By Test Location
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Test Location
        • 7.3.1.2.4. By End User
    • 7.3.2. France Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Test Location
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Test Location
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Test Location
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Test Location
        • 7.3.5.2.4. By End User

8. Asia Pacific Point-Of-Care Molecular Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By Test Location
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Test Location
        • 8.3.1.2.4. By End User
    • 8.3.2. India Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Test Location
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Test Location
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Test Location
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Test Location
        • 8.3.5.2.4. By End User

9. Middle East & Africa Point-Of-Care Molecular Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By Test Location
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Point-Of-Care Molecular Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Test Location
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Point-Of-Care Molecular Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Test Location
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Point-Of-Care Molecular Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Test Location
        • 9.3.3.2.4. By End User

10. South America Point-Of-Care Molecular Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By Test Location
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Point-Of-Care Molecular Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Test Location
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Point-Of-Care Molecular Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Test Location
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Point-Of-Care Molecular Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Test Location
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Point-Of-Care Molecular Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Siemens Healthineers AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Quidel Corporation
  • 15.3. F. Hoffman-La Roche Ltd.
  • 15.4. Danaher Corporation
  • 15.5. Beckton & Dickinson Company
  • 15.6. Trinity Biotech plc
  • 15.7. Thermo Fisher Scientific Inc
  • 15.8. bioMerieux S.A.
  • 15.9. DiaSorin S.p.A
  • 15.10. AccuBioTech Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer